Allogeneic hematopoietic stem cell transplantation (HSCT) is a curative treatment for some hematologic malignancies. As the overall number of survivors continues to increase, studies systematically examining outcomes in long-term survivors are needed. We studied the clinical and quality-of-life outcomes in HSCT recipients surviving 5 or more years from HSCT. Since 1993, 262 patients with hematologic malignancies received a T cell-depleted myeloablative HSCT from an HLA-identical sibling at a single center. Ninety-two survived beyond 5 years from HSCT (median follow-up 9.4 years, range: 5.1-15.3). Median age at transplantation was 35 years (range: 10-56). Twenty-two (24%) received a bone marrow transplant, and 70 (76%) received a peripheral ...
Background: Allogeneic hematopoietic stem cell transplantation (alloHSCT) is the only curative tre...
Background: Allogeneic hematopoietic stem cell transplantation (alloHSCT) is the only curative treat...
Hematopoietic stem cell transplantation (HSCT) is a standard treatment after disease relapse and fai...
Allogeneic hematopoietic stem cell transplantation (HSCT) is a curative treatment for some hematolog...
AbstractThe number of survivors after allogeneic hematopoietic stem cell transplantation (HSCT) cont...
Hematopoietic stem cell transplantation (HSCT) is a standard treatment after disease relapse and fai...
We analyzed the outcome of allogeneic hematopoietic stem cell transplantation (HSCT) over the past 2...
AbstractWe analyzed the outcomes of patients who survived disease-free for 1 year or more after a se...
AbstractLong-term morbidity after hematopoietic cell transplantation (HCT) is unknown. The risk of p...
We analyzed the outcome of allogeneic hematopoietic stem cell transplantation (HSCT) over the past 2...
Background: Allogeneic hematopoietic stem cell transplantation (alloHSCT) is the only curative treat...
View full abstracthttps://openworks.mdanderson.org/leading-edge/1007/thumbnail.jp
We assessed late mortality in 1479 individuals who had survived 2 or more years after allogeneic hem...
Background: Allogeneic hematopoietic stem cell transplantation (alloHSCT) is the only curative tre...
Background: Allogeneic hematopoietic stem cell transplantation (alloHSCT) is the only curative tre...
Background: Allogeneic hematopoietic stem cell transplantation (alloHSCT) is the only curative tre...
Background: Allogeneic hematopoietic stem cell transplantation (alloHSCT) is the only curative treat...
Hematopoietic stem cell transplantation (HSCT) is a standard treatment after disease relapse and fai...
Allogeneic hematopoietic stem cell transplantation (HSCT) is a curative treatment for some hematolog...
AbstractThe number of survivors after allogeneic hematopoietic stem cell transplantation (HSCT) cont...
Hematopoietic stem cell transplantation (HSCT) is a standard treatment after disease relapse and fai...
We analyzed the outcome of allogeneic hematopoietic stem cell transplantation (HSCT) over the past 2...
AbstractWe analyzed the outcomes of patients who survived disease-free for 1 year or more after a se...
AbstractLong-term morbidity after hematopoietic cell transplantation (HCT) is unknown. The risk of p...
We analyzed the outcome of allogeneic hematopoietic stem cell transplantation (HSCT) over the past 2...
Background: Allogeneic hematopoietic stem cell transplantation (alloHSCT) is the only curative treat...
View full abstracthttps://openworks.mdanderson.org/leading-edge/1007/thumbnail.jp
We assessed late mortality in 1479 individuals who had survived 2 or more years after allogeneic hem...
Background: Allogeneic hematopoietic stem cell transplantation (alloHSCT) is the only curative tre...
Background: Allogeneic hematopoietic stem cell transplantation (alloHSCT) is the only curative tre...
Background: Allogeneic hematopoietic stem cell transplantation (alloHSCT) is the only curative tre...
Background: Allogeneic hematopoietic stem cell transplantation (alloHSCT) is the only curative treat...
Hematopoietic stem cell transplantation (HSCT) is a standard treatment after disease relapse and fai...